Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684631 | 1.00 | LMNA (0.45) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL1150088 | 0.85 | LMNA (0.46) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL1150084 | 0.85 | LMNA (0.46) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL1150086 | 0.85 | LMNA (0.46) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL300179 | 0.84 | LMNA (0.46) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL300178 | 0.84 | LMNA (0.46) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL294672 | 0.82 | LMNA (0.51) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL4959684 | 0.82 | LMNA (0.69) | LMNATSHRRAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL2168536 | 0.81 | LMNA (0.67) | LMNATSHRRAB9ATDP1CYP1A2 | |
| SCHEMBL2170337 | 0.81 | LMNA (0.67) | LMNATSHRRAB9ATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700799-B2 | Method for producing (2-formyl-1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7498459-B2 | Method for producing (1-alkenyl)cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-23 | — | — | US | disclosed |
| EP-1728781-A1 | PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES | Sumitomo Chemical Company, Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | ACSL3, ACSL1, ARL1 | LMNA 2696/4885TSHR 3074/4885RAB9A 3852/4885 |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | ACSL3, ARL1, ACSL1 | LMNA 3763/4885TSHR 3751/4885RAB9A 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.